BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38485750)

  • 21. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [
    Xu HQ; Song LJ; Ding CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of an individualized RNA binding protein-based prognostic signature for diffuse large B-cell lymphoma.
    Xie Y; Luo X; He H; Pan T; He Y
    Cancer Med; 2021 Apr; 10(8):2703-2713. PubMed ID: 33749163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma.
    Wu Z; Guan Q; Han X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Wang X; Zhang H
    Aging (Albany NY); 2021 Oct; 13(19):22947-22962. PubMed ID: 34610582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Lee YS; Liu J; Fricano KA; Webb EM; Toolsie DR; Jones S; Rhoads JA; Vij R; Cashen AF; Abboud CN; Westervelt P; Bartlett NL; Dipersio JF; Kreisel FH; Lim KH
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2199-2204. PubMed ID: 28847710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.
    Ceriani L; Milan L; Cascione L; Gritti G; Dalmasso F; Esposito F; Pirosa MC; Schär S; Bruno A; Dirnhofer S; Giovanella L; Hayoz S; Mamot C; Rambaldi A; Chauvie S; Zucca E
    Hematol Oncol; 2022 Feb; 40(1):11-21. PubMed ID: 34714558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
    Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
    Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a prognostic metabolic gene signature in diffuse large B-cell lymphoma.
    Wang H; Shao R; Liu W; Tang H; Lu Y
    J Cell Mol Med; 2021 Jul; 25(14):7066-7077. PubMed ID: 34128320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.
    Xu PP; Shen R; Shi ZY; Cheng S; Wang L; Liu Y; Zhang L; Huang R; Ma X; Wu X; Yao H; Yu Y; Zhao WL
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1051-e1058.e1. PubMed ID: 36182550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prognostic 15-gene model based on differentially expressed genes among metabolic subtypes in diffuse large B-cell lymphoma.
    Hou J; Guo P; Lu Y; Jin X; Liang K; Zhao N; Xue S; Zhou C; Wang G; Zhu X; Hong H; Chen Y; Lu H; Wang W; Xu C; Han Y; Cai S; Liu Y
    Pathol Oncol Res; 2023; 29():1610819. PubMed ID: 36816541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and validation of nomogram prognostic model for predicting OS in patients with diffuse large B-cell lymphoma: a cohort study in China.
    Li X; Xu Q; Gao C; Yang Z; Li J; Sun A; Wang Y; Lei H
    Ann Hematol; 2023 Dec; 102(12):3465-3475. PubMed ID: 37615680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of pretreatment red blood cell distribution width in primary diffuse large B-cell lymphoma of the central nervous system for 3P medical approaches in multiple cohorts.
    Li D; Li S; Xia Z; Cao J; Zhang J; Chen B; Zhang X; Zhu W; Fang J; Liu Q; Hua W
    EPMA J; 2022 Sep; 13(3):499-517. PubMed ID: 36061828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of 5-hydroxymethylcytosine as a Poor Prognostic Factor for Primary Testicular Diffuse Large B-cell Lymphoma.
    Shen Y; Wang L; Ou J; Wang B; Cen X
    Int J Med Sci; 2022; 19(2):225-232. PubMed ID: 35165508
    [No Abstract]   [Full Text] [Related]  

  • 35. Development and validation of a cuproptosis-associated prognostic model for diffuse large B-cell lymphoma.
    Zhang B; Zhang T; Zheng Z; Lin Z; Wang Q; Zheng D; Chen Z; Ma Y
    Front Oncol; 2022; 12():1020566. PubMed ID: 36713586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma.
    Wang J; Wang Y; Wan L; Chen X; Zhang H; Yang S; Zhong L
    Front Immunol; 2023; 14():1230017. PubMed ID: 37790933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.
    Trabucco SE; Sokol ES; Maund SL; Moore JA; Frampton GM; Albacker LA; Oestergaard MZ; Venstrom J; Sehn LH; Bolen CR
    Future Oncol; 2021 Nov; 17(31):4171-4183. PubMed ID: 34313135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
    Zhou LH; Feng YQ; Hu YX; Huang H
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma].
    Wang Y; Shi ZY; Shi Q; Wang S; Zhang MC; Shen R; He Y; Qiu HL; Yi HM; Dong L; Wang L; Cheng S; Xu PP; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):321-327. PubMed ID: 37357002
    [No Abstract]   [Full Text] [Related]  

  • 40. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.